Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

Caligiuri, Michael A.; Murray, Christine; Robertson, Michael J.; Wang, Eunice S.; Cochran, Keith; Cameron, Christine; Schow, Peter; Ross, Mary Ellen; Klumpp, Thomas R.; Soiffer, Robert J.

doi:10.1172/jci116161

Cited by 236 publications

(151 citation statements)

References 45 publications

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…[42][43][44][45][46] One commonly employed method for inducing NK cell proliferation and activation in vivo is low-dose IL-2 administration but this has a more pronounced effect on CD56 bright (CD16 dim/2 ) cells, which express high-affinity IL-2 receptors, than on CD56 dim (CD16 bright ) cells. 42,44,47 Even if NK cell numbers in patients' peripheral blood doubles following low-dose IL-2 administration, ADCC ability of PBMC was shown to not significantly increase in one study 42 and to increase only 30% in another. 48 The ease with which CD16 1 Vg9Vd2 T cells can be expanded and their potential for antitumor cytotoxicity through multiple, additional mechanisms suggests they warrant further in vivo clinical evaluation in parallel with studies evaluating other immune effector cell populations.…”

Section: Discussionmentioning

confidence: 99%

Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab

Tokuyama

Hagi

Mattarollo

et al. 2008

Intl Journal of Cancer

134

121

View full text Add to dashboard Cite

Vc9Vd2 T cells exert potent cytotoxicity toward various tumor cells and adoptive transfer of Vc9Vd2 T cells is an attractive proposition for cell based immunotherapy. Vc9Vd2 T cells expanded in the presence of Zoledronate and IL-2 express CD16 (FccRIII), which raises the possibility that Vc9Vd2 T cells could be used in conjunction with tumor targeting monoclonal antibody drugs to increase antitumor cytotoxicity by antibody dependent cellular cytotoxicity (ADCC). Cytotoxic activity against CD20-positive B lineage lymphoma or chronic lymphocytic leukemia (CLL) and HER2-positive breast cancer cells was assessed in the presence of rituximab and trastuzumab, respectively. Cytotoxicity of Vc9Vd2 T cells against CD20-positive targets was higher when used in combination with rituximab. Similarly, Vc9Vd2 T cells used in combination with trastuzumab resulted in greater cytotoxicity against HER2-positive cells in comparison with either agent alone and this effect was restricted to the CD16 1 Vc9Vd2 T cell population. Our results show that CD16 1 Vc9Vd2 T cells recognize monoclonal antibody coated tumor cells via CD16 and exert ADCC similar to that observed with NK cells, even when target cells are relatively resistant to monoclonal antibodies or Vc9Vd2 T cells alone. Combination therapy involving ex vivo expanded CD16 1 Vc9Vd2 T cells and monoclonal antibodies may enhance the clinical outcomes for patients treated with monoclonal antibody therapy. '

show abstract

Section: Discussionmentioning

confidence: 99%

Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab

Tokuyama

Hagi

Mattarollo

et al. 2008

Intl Journal of Cancer

134

121

View full text Add to dashboard Cite

show abstract

“…5,6 Clinical trials attempting to harness the antitumor effect of NK cells, either through in vivo or in vitro activation, have met with only modest success to date. [7][8][9] However, over the past decade our knowledge of how NK cells recognize target cells using an integration of activating and inhibitory receptors now points toward potential clinical utility for the treatment of leukemia and other malignancies. In this review we summarize our current understanding of the receptors involved in NK cell recognition of tumor targets and discuss their potential clinical role in immunotherapy of leukemia with and without hematopoietic stem cell transplantation.…”

Section: Introductionmentioning

confidence: 99%

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

Farag

Fehniger

Ruggeri

et al. 2002

Blood

455

355

View full text Add to dashboard Cite

“…IL-2 effectively stimulates the anti-tumour activity of natural killer (NK) cells and other cytotoxic cells in the majority of treated patients (Caligiuri et al, 1993), but the effects on tumour burden and on the survival of patients have, as yet, been disappointing. The detailed mechanisms that explain the poor clinical outcome are not known.…”

mentioning

confidence: 99%

The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation

Johansson

Landström²,

Hellstrand³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Summary A syngeneic, androgen-sensitive Dunning R3327 rat prostatic adenocarcinoma was transplanted bilaterally in the flanks of male Copenhagen Fisher rats. Approximately 3 months after implantation, when the tumours had a median volume of 150 mm3, one group of rats was treated with histamine alone (4 mg kg-1 subcutaneously on week days), another group with human recombinant interleukin 2 (IL-2) alone (425 IU kg-' continuous infusion) and a third group with both histamine and IL-2 during 6 weeks. Tumours on one flank were irradiated (6 Gy once daily for 3 days to a total dose of 18 Gy) beginning 1 week after the onset of treatment with histamine and / or IL-2. The contralateral tumour served as the intra-animal control. The tumour volumes were determined weekly. The growth curves showed that all three drug treatments were effective in delaying growth, but when used individually did not cause tumour shrinkage. Radiation was the most effective single agent, but when used alone the shrinkage did not occur until 2 weeks after irradiation. When combined with the drugs, more rapid and extensive growth delay and/or shrinkage was seen. The growth curves showed clear differences between the different treatments. The combination of the three agents was the most effective of all. The most striking difference between radiation alone and radiation plus biotherapy was the time at which a tumour response was detectable. Thus, active biotherapy alone and especially in a combination with histamine and radiotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.

show abstract

Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

Abstract: The immunologic consequences of prolonged infusions of rIL-2 in doses that produce physiologic serum concentrations of this cytokine were investigated. rIL Invest. 1993. 91:123-132.)

Cited by 236 publications

References 45 publications

Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab

Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation

Contact Info

Product

Resources

About